Current affairs News Science, Health & Technology

Europe approves first gene therapy

Europe approves first gene therapy

In a ground-breaking move, the first drug that can rectify faults in the genetic code has been given the go-ahead in Europe, directing the way for the development of new drugs in the future.

The Glybera drug, developed by UniQure, is to be used to counteract a disorder known as Lipoprotein Lipase Deficiency, a syndrome that affects around two people in every million and can cause critical inflammation of the pancreas. Sufferers can not handle fat particles in the blood and the end result can be lethal.

A single treatment of Glybera is enough to treat the disorder.

Although two gene therapies have previously been approved in China, the drug is the first to be endorsed by the European Medicines Agency with the European Commission and should be obtainable next year.

The drug will cost £1 million per patient, and governments are in debate over ways to pay for the drug before it is released on to the market in 2013. Some may decide to pay £200,000 per year over a five-year period.

This type of therapy will no doubt raise many questions and is just the beginning as some of the world’s leading pharmaceutical companies start researching different types of gene therapy.

Chief executive of UniQure John Aldag said: “This final approval of Glybera from the European Commission marks a major step forward in making gene therapies available not only for Lipoprotein Lipase Deficiency, but also for a large number of rare diseases with a very high unmet medical need.”

James Clark 

More in Current Affairs

Understanding Interpol notices and arrest warrants in the UAE

The editorial unit

The role of expert business plan writers in securing funding for startups

The editorial unit

What you need to know about full fibre broadband

The editorial unit

“Chill the VR Out”: YourHaven’s hilarious and heartfelt campaign for Mental Health Awareness Month

The editorial unit

Women of Ireland have rolled over for long enough: The 8th and the long walk to abortion rights

Emma Kiely

Changes to expect during menopause

The editorial unit

Why Equity Linked Savings Schemes is a preferred tax saving?

The editorial unit

How the world’s top designers would rebrand political parties

The editorial unit

Royal baby furore: Proof that the British monarchy is still popular?

Eoin O’Sullivan-Harris